Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 10/12/18 (What's New)

Summary

  • The use of darunavir/ritonavir monotherapy for maintenance of viral suppression has been evaluated in several trials
    • In the PIVOT trial, boosted PI monotherapy (majority of patients received darunavir/ritonavir) was noninferior to continuing triple-drug antiretroviral therapy for the primary endpoint of loss of future drug options[Paton 2015]
    • The MONET trial found that noninferiority of darunavir/ritonavir monotherapy to darunavir/ritonavir monotherapy plus NRTIs was not maintained for 144 weeks of therapy[Arribas 2012]

Action required